AC Immune SA (ACIU) News
NASDAQ: ACIUHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.50-0.05 (-1.96%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ACIU news summary
We found 11 recent headlines mentioning AC Immune SA (ACIU): 3 in the past week and 10 in the past 30 days, most often from Nasdaq. For price context, ACIU is down 1.96% at $2.50. The most recent story, "AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know", was published by Nasdaq on Oct 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest AC Immune SA headlines
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowAgios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.NasdaqAGIO, NVO, ALDX, ACIU
- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.NasdaqNVS, IONS, ACIU, PGEN
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkNVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.NasdaqNVO, ALDX, ACIU, PGEN
- Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyMRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.NasdaqMRK, AMRN, ACIU, ARQT
- Here's Why You Should Add URGN Stock to Your Portfolio NowUroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.NasdaqURGN, TEVA, ACIU, PGEN
- KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsKodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.NasdaqKOD, REGN, ACIU, PGEN
- Teva's Branded Drugs Take Center Stage in Its Growth StrategyTeva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.NasdaqTEVA, SNY, AMRN, ACIU
- Vertex Posts Positive Phase II Data on Kidney Disease DrugVRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.NasdaqVRTX, ALDX, ACIU, PGEN
- Gilead Expands Lenacapavir Access With New PAHO Deal in Latin AmericaGILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.NasdaqGILD, ALDX, ACIU, PGEN
- GSK Inks $750M Deal to Add Experimental Blood Cancer TherapyGSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.NasdaqGSK, ALDX, ACIU, PGEN
- ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Upargenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.NasdaqARGX, ACIU, AMRX, PGEN